Tower Research Capital (TRC)’s Metagenomi Therapeutics MGX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.31K	Buy	5,300 +5,258	+12,519%	+$7.03K	﹤0.01%	4223
2026 Q1	$56	Sell	42 -9,261	-100%	-$14.4K	﹤0.01%	5028
2025 Q4	$15.1K	Buy	+9,303	New	+$20.1K	﹤0.01%	3309
2025 Q3	–	Sell	-12,375	Closed	-$18.3K	–	5692
2025 Q2	$18.3K	Buy	12,375 +2,880	+30%	+$4.51K	﹤0.01%	3736
2025 Q1	$12.9K	Buy	9,495 +5,623	+145%	+$13.4K	﹤0.01%	3415
2024 Q4	$14K	Sell	3,872 -1,375	-26%	-$3.32K	﹤0.01%	3487
2024 Q3	$11.4K	Buy	5,247 +872	+20%	+$3.02K	﹤0.01%	3668
2024 Q2	$17.9K	Buy	4,375 +3,919	+859%	+$26.9K	﹤0.01%	3814
2024 Q1	$4.81K	Buy	+456	New	+$5.24K	﹤0.01%	4624

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tower Research Capital (TRC)'s MGX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Metagenomi Therapeutics (MGX) stake by 12,519% in Q2 2026, buying an estimated $7.03K and bringing the position to 5,300 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #4223.

Tower Research Capital (TRC) first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $18.3K in Q2 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Tower Research Capital (TRC) held 5,300 shares of Metagenomi Therapeutics worth $6.31K as of Q2 2026.
Tower Research Capital (TRC) bought 5,258 Metagenomi Therapeutics shares in Q2 2026, an estimated $7.03K.
Metagenomi Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4223 holding.
Tower Research Capital (TRC) first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s Metagenomi Therapeutics position peaked at $18.3K in Q2 2025.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.